131 related articles for article (PubMed ID: 11555572)
21. [Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Junker A; Wiedemann GJ; Possinger K
MMW Fortschr Med; 2002 Jan; 144(5):46-8. PubMed ID: 11883037
[TBL] [Abstract][Full Text] [Related]
22. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
23. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Illiger HJ
Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
[No Abstract] [Full Text] [Related]
24. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
25. Toremifene and letrozole for advanced breast cancer.
Med Lett Drugs Ther; 1998 Apr; 40(1024):43-5. PubMed ID: 9580744
[No Abstract] [Full Text] [Related]
26. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
Forciniti S
Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
[No Abstract] [Full Text] [Related]
27. [Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition].
Internist (Berl); 1997 Mar; 38(3 Suppl Selektive):1-16. PubMed ID: 9541667
[No Abstract] [Full Text] [Related]
28. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
29. Anastrozole: a new selective nonsteroidal aromatase inhibitor.
Goss PE; Tye LM
Oncology (Williston Park); 1997 Nov; 11(11):1697-703; discussion 1707-8. PubMed ID: 9394367
[TBL] [Abstract][Full Text] [Related]
30. Anastrozole-induced hepatotoxicity.
Zapata E; Zubiaurre L; Bujanda L; Piérola A
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1233-4. PubMed ID: 17033446
[TBL] [Abstract][Full Text] [Related]
31. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
Gori S; Anastasi P; Marrocolo F
Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
[No Abstract] [Full Text] [Related]
32. [Aromatase inhibitors: pharmacological aspects].
de Crémoux P
Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
[TBL] [Abstract][Full Text] [Related]
33. [Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Song ST; Jiang ZF
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):510-2. PubMed ID: 16188157
[No Abstract] [Full Text] [Related]
34. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Bergmann L
Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
[No Abstract] [Full Text] [Related]
35. Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Ingle JN
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S17. PubMed ID: 21172079
[No Abstract] [Full Text] [Related]
36. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Clemons M; Coleman RE; Verma S
Cancer Treat Rev; 2004 Jun; 30(4):325-32. PubMed ID: 15145507
[TBL] [Abstract][Full Text] [Related]
38. Appraising adjuvant aromatase inhibitor therapy.
Perez EA
Oncologist; 2006; 11(10):1058-69. PubMed ID: 17110624
[TBL] [Abstract][Full Text] [Related]
39. [The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Porpiglia M; Genta F; Vicelli R; De Nicola B; Ferraris F; Piccinno R; Benedetto C
Minerva Ginecol; 2002 Apr; 54(2):115-31. PubMed ID: 12032450
[TBL] [Abstract][Full Text] [Related]
40. ATAC trial update.
Del Mastro L; Venturini M
Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811447
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
